Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

✍ Scribed by Yves Benhamou; Herve Fleury; Pascale Trimoulet; Isabelle Pellegrin; Renaud Urbinelli; Christine Katlama; Willy Rozenbaum; Gwenael Le Teuff; Aldo Trylesinski; Christophe Piketty

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 157 KB
• Volume: 43
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.21055

✦ Synopsis

for the TECOVIR Study Group Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg/d), administered as a part of anti-retroviral therapy, in a large cohort of HIV/HBV-coinfected patients. Sixty-five HIV/HBV-coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log 10 copies/mL at TDF initiation and who had stored serum samples before and during TDF therapy were included. Serum HBV DNA was measured on stored samples. The median follow-up period was 12 (Q1-Q3: 8-17) months. Serum hepatitis B e antigen (HBeAg) was positive in 54 patients (83.1%). Fifty-two patients (80.0%) were receiving lamivudine (LAM) (150 mg twice a day), and 68.8% had documented LAM resistance at baseline. Among HBeAg-positive patients, the median reduction from baseline (8.17; Q1-Q3 ‫؍‬ 7.30-8.30 log 10 copies/mL) of serum HBV DNA was 4.56 log 10 copies/mL (Q1-Q3 ‫؍‬ 3.33-5.55) (P < .0001). In HBeAg-negative patients, serum HBV DNA decline from baseline (4.83; Q1-Q3 ‫؍‬ 2.69-6.40 log 10 copies/mL) was 2.53 log 10 copies/mL (Q1-Q3 ‫؍‬ 0.39-4.10). At the end of the study, HBV DNA became undetectable in 29.6% and 81.6% of the HBeAg-positive and HBeAg -negative patients, respectively. Serum HBeAg became negative in 4 patients, 2 of whom acquired serum hepatitis B e antibody. In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients. (HEPATOLOGY 2006;43:548-555.